Skip to main
BCDA

BioCardia Inc. (BCDA) Stock Forecast & Price Target

BioCardia Inc. (BCDA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioCardia Inc is advancing its CardiAMP autologous mononuclear cell therapy platform with promising results from the Phase 3 clinical trial, which demonstrated significant reductions in heart death equivalents and major adverse cardiovascular and cerebrovascular events (MACCE), particularly among high-risk patients. The therapy showed that patients receiving the treatment in conjunction with heart failure medication experienced improved quality of life and lower mortality rates over a 24-month period. Additionally, the ongoing enrollment in its CardiALLO platform for ischemic heart failure and acute respiratory distress syndrome suggests a strong pipeline for addressing unmet medical needs in the cardiovascular and pulmonary domains, potentially driving growth for the company.

Bears say

BioCardia Inc. faces a negative outlook primarily due to its CardiAMP HF clinical program's failure to meet key composite endpoints related to heart failure, which raises concerns over the efficacy of its therapies. Furthermore, potential risks include the prospect of inconclusive clinical trials and challenges in securing sufficient funding to advance its drug candidates, which could hinder development. Additionally, the absence of projections for the CardiALLO program introduces further uncertainty regarding the company's ability to achieve its financial goals and maintain investor confidence.

BioCardia Inc. (BCDA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioCardia Inc. (BCDA) Forecast

Analysts have given BioCardia Inc. (BCDA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioCardia Inc. (BCDA) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioCardia Inc. (BCDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.